The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial.
本发明涉及替代的偶氮
蒽衍
生物或其药学上可接受的盐,其调节人类GLP-1受体,并可用于治疗调节人类GLP-1受体有益的疾病、紊乱或病症,如2型糖尿病。本发明还涉及包含这些化合物的药物组合物以及这些化合物和组合物在治疗调节人类GLP-1受体有益的这些疾病、紊乱或病症中的使用。